Dongfang Liu Sells 15,000 Shares of Nuvation Bio (NYSE:NUVB) Stock

Nuvation Bio Inc. (NYSE:NUVB) insider Dongfang Liu sold 15,000 shares of the stock in a transaction on Wednesday, November 19th. The stock was sold at an average price of $5.10, for a total transaction of $76,500.00. Following the sale, the insider directly owned 18,000 shares of the company’s stock, valued at $91,800. This represents a 45.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Dongfang Liu also recently made the following trade(s):

• On Wednesday, November 19th, Dongfang Liu sold 15,000 shares of Nuvation Bio stock. The shares were sold at an average price of $5.10, for a total transaction of $76,500.00.
• On Monday, November 17th, Dongfang Liu sold 15,000 shares of Nuvation Bio stock. The stock was sold at an average price of $4.76, for a total transaction of $71,400.00.
• On Monday, November 17th, Dongfang Liu sold 15,000 shares of Nuvation Bio stock. The stock was sold at an average price of $4.76, for a total value of $71,400.00.

Nuvation Bio Stock Up 49.0%

Shares of Nuvation Bio stock traded up $2.35 during trading on Wednesday, reaching $7.15. The stock had a trading volume of 58,912,933 shares, compared to its average volume of 5,464,649. The company has a market capitalization of $2.45 billion, a price-to-earnings ratio of -11.17 and a beta of 1.49. The stock has a fifty day moving average price of $4.04 and a two-hundred day moving average price of $2.96. Nuvation Bio Inc. has a 52 week low of $1.54 and a 52 week high of $7.35. The company has a current ratio of 8.48, a quick ratio of 8.39 and a debt-to-equity ratio of 0.14.

Nuvation Bio (NYSE:NUVB) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01. The business had revenue of $13.12 million during the quarter, compared to the consensus estimate of $7.48 million. Nuvation Bio had a negative return on equity of 54.99% and a negative net margin of 813.07%. Sell-side analysts predict that Nuvation Bio Inc. will post -0.36 EPS for the current fiscal year.

Institutional Investors Weigh In On Nuvation Bio

Hedge funds have recently bought and sold shares of the company. Parallel Advisors LLC raised its stake in Nuvation Bio by 51.9% in the third quarter. Parallel Advisors LLC now owns 7,597 shares of the company’s stock valued at $28,000 after buying an additional 2,597 shares during the period. LCM Capital Management Inc increased its holdings in shares of Nuvation Bio by 29.2% during the 3rd quarter. LCM Capital Management Inc now owns 15,500 shares of the company’s stock worth $57,000 after acquiring an additional 3,500 shares during the last quarter. Mackenzie Financial Corp increased its holdings in shares of Nuvation Bio by 38.8% during the 3rd quarter. Mackenzie Financial Corp now owns 15,746 shares of the company’s stock worth $58,000 after acquiring an additional 4,400 shares during the last quarter. Integrated Wealth Concepts LLC raised its stake in Nuvation Bio by 21.9% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 24,610 shares of the company’s stock valued at $91,000 after acquiring an additional 4,419 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Nuvation Bio by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 108,547 shares of the company’s stock valued at $191,000 after purchasing an additional 4,608 shares during the last quarter. 61.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

NUVB has been the topic of a number of research reports. Citigroup reissued a “market outperform” rating on shares of Nuvation Bio in a research report on Tuesday, November 4th. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Nuvation Bio in a research report on Friday, September 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Nuvation Bio in a report on Wednesday, October 8th. Citizens Jmp lifted their target price on Nuvation Bio from $6.00 to $8.00 and gave the company a “market outperform” rating in a research report on Tuesday, November 4th. Finally, Jefferies Financial Group assumed coverage on Nuvation Bio in a research report on Tuesday, September 30th. They set a “buy” rating and a $10.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $9.00.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.